Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal ( WINNIPEG Manitoba

Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused biopharmaceutical company, today announced that the results from its Phase 2 MEND-CABG trial are featured in a peer reviewed article in the June edition of The Journal of Thoracic and Cardiovascular Surgery, published by the American Association of Thoracic Surgery.

The article, titled, "Effects of pyridoxal-5-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study", outlines evidence of MC-1's potential efficacy in reducing ischemic reperfusion injury. Additionally, the article presents further detail, background information and analysis of Medicure's positive MEND-CABG study.

"We are pleased that our novel cardioprotective product MC-1 is being recognized by one of the leading cardiovascular surgery journals," stated Medicure's President and CEO, Albert D. Friesen, PhD. "The results from MEND-CABG clearly show that patients treated with MC-1 experienced clinically meaningful reductions in the composite endpoint, driven by a pronounced reduction in large non-fatal myocardial infarctions, which comprise the majority of events after CABG surgery. We eagerly anticipate the results of the ongoing pivotal Phase 3 MEND-CABG II registration trial."

Additional Clinical Data

The article also includes new data from a post-hoc analysis demonstrating a statistically significant lower incidence of atrial fibrillation in the MC-1 groups (250 mg @.7% and 750 mg @.0%) compared to the placebo group (11.9%) between post operative day (POD) four and the end of the trial.

"Atrial fibrillation is one of the most common complications after CABG surgery, and is associated with a significant increase in morbidity and mortality, as well as prolonged hospital stay and increased hospital costs," commented Dr. Friesen. "Prevention of atrial fibrilla
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

Post Your Comments:

( WINNIPEG Manitoba - (May 31 2007) Med...)Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal,Health